Cambiar Investors LLC Gilead Sciences, Inc. Transaction History

Cambiar Investors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 28, 2022	SELL	$59.54 - $68.01 $21,017 - $24,007	-353 Reduced 5.29%	6,325 $390,000
Q2 2022 Aug 05, 2022	BUY	$57.72 - $65.01 $171,717 - $193,404	2,975 Added 80.34%	6,678 $413,000
Q3 2021 Oct 22, 2021	BUY	$67.69 - $73.03 $1,692 - $1,825	25 Added 0.68%	3,703 $259,000
Q1 2021 May 14, 2021	BUY	$60.0 - $68.46 $220,680 - $251,795	3,678 New	3,678 $238,000
Q3 2020 Oct 21, 2020	SELL	$62.1 - $78.08 $22.8 Million - $28.7 Million	-367,534 Closed	0 $0
Q2 2020 Aug 03, 2020	SELL	$72.34 - $84.0 $10.3 Million - $11.9 Million	-141,865 Reduced 27.85%	367,534 $28.3 Million
Q1 2020 Apr 30, 2020	SELL	$62.63 - $80.22 $9.83 Million - $12.6 Million	-156,944 Reduced 23.55%	509,399 $38.1 Million
Q4 2019 Feb 06, 2020	BUY	$61.62 - $67.78 $815,417 - $896,932	13,233 Added 2.03%	666,343 $43.3 Million
Q3 2019 Oct 17, 2019	BUY	$62.51 - $69.0 $40.8 Million - $45.1 Million	653,110 New	653,110 $41.4 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Cambiar Investors LLC, based on Form 13F filings with the SEC.

Stay updated on Cambiar Investors LLC with notifications on news.